Matricel
Matricel GmbH is a German medical device manufacturer producing bioresorbable Class III collagen implants and membranes (Remaix, ACI-Maix, Cartimaix, creos xenoprotect) for dental, orthopedic cartilage, dermal, and nerve regeneration, serving clinicians, hospitals, and OEM medical-device partners globally through distribution partnerships and contract manufacturing.
- Company typePrivate
- Founded2001
- HeadquartersHerzogenrath, Germany
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Matricel does
Matricel GmbH develops, manufactures, and markets bioresorbable Class III medical devices based on proprietary collagen scaffold technologies for regenerative medicine applications. Founded in 2001 as a spin-off from the Helmholtz Institute of RWTH Aachen University and headquartered in Herzogenrath, Germany, the company operates as a subsidiary of Envista Holdings Corporation and employs 11–50 people. Its core technology platform combines proprietary directional solidification and freeze-drying to produce open-porous collagen matrices with oriented channel structures, EDC/NHS zero-length cell-compatible crosslinking that controls biodegradation without toxic residuals, and high-purity collagen and elastin extraction from veterinary-controlled animal sources.
The commercial product portfolio is anchored by Remaix (and its Nobel Biocare-branded variant creos xenoprotect), a bioresorbable dental collagen/elastin barrier membrane for guided bone and tissue regeneration (GBR/GTR), and ACI-Maix/Cartimaix bioresorbable membranes used in cartilage defect treatment, including as a key component of Vericel's MACI autologous chondrocyte implant under a long-term supply agreement. Research-stage products extend the platform into dermal regeneration (Novomaix, CE-marked 2013 for full-thickness burn and reconstructive surgery defects), peripheral nerve guidance (Neuromaix), and endochondral bone-cartilage ossification (E.CH.O). All products are manufactured in GMP-compliant cleanroom facilities in Germany, with clinical development supported by collaborations with RWTH Aachen, Fraunhofer ILT, Forschungszentrum Jülich, and EU consortiums.
The business model combines direct medical device sales with multi-channel distribution: Nobel Biocare globally distributes dental membranes under the creos xenoprotect brand across Europe, the US (post-FDA 2013), Canada (2015), and Mexico/Central America (Cofepris 2015); 2med GmbH distributes Cartimaix in Germany and Austria; and Matricel sells directly to hospitals, burn wound centers, dental clinics, and orthopedic surgery departments. A secondary revenue stream comes from contract manufacturing of collagen-containing products for pharmaceutical and medical device manufacturers, plus supply of pharmaceutical excipients. Pricing is quote-based B2B enterprise pricing, with no public price disclosure. Regulatory clearances across Europe (CE 2009), the US (FDA 2013), Canada, and Mexico underpin the global commercial reach.
Matricel firmographics
Firmographics- Name
- Matricel
- Legal name
- Matricel GmbH
- Website
- https://matricel.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Matricel GmbH is a German medical device manufacturer producing bioresorbable Class III collagen implants and membranes (Remaix, ACI-Maix, Cartimaix, creos xenoprotect) for dental, orthopedic cartilage, dermal, and nerve regeneration, serving clinicians, hospitals, and OEM medical-device partners globally through distribution partnerships and contract manufacturing.
- Ownership category
- akta.pro rank
Matricel industry classification
Industry- Product category
- Regenerative Medicine Medical Devices
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841), Dental Equipment & Supplies (3843)
- akta.pro primary industry
- Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)
- akta.pro secondary industries
- Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
Keywords
Where Matricel is headquartered
LocationHeadquarters
- HQ city
- Herzogenrath
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Matricel business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Sales: Sale of bioresorbable Class III collagen implants for regenerative medicine applications including dental GBR/GTR (Remaix), orthopedic cartilage regeneration (Cartimaix), and skin regeneration (Novomaix). Products are approved in Europe, US, Canada and other territories.
- Contract Manufacturing: Contract manufacturing services for pharmaceutical companies and medical device manufacturers, producing collagen-containing products to specification.
- Pharmaceutical Excipients: Development and supply of pharmaceutical excipients for applications in medicine and biotechnology.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B enterprise pricing through distribution partners and direct sales |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
Matricel product offering
Product offeringCore offering
Matricel develops, manufactures, and markets bioresorbable Class III collagen implants for regenerative medicine applications, including dental barrier membranes (Remaix, creos xenoprotect), cartilage regeneration membranes (ACI-Maix, Cartimaix), dermal regeneration matrices (Novomaix), nerve guidance conduits (Neuromaix), and bone-cartilage scaffolds (E.CH.O). The company also provides contract manufacturing services for collagen-containing products to pharmaceutical and medical device firms.
Product overview
Matricel develops, manufactures, and markets bioresorbable collagen implant products for regenerative medicine applications. The product portfolio centers on Class III medical devices including Remaix (dental barrier membrane for GBR/GTR), ACI-Maix and Cartimaix (cartilage regeneration membranes), and creos xenoprotect (dental membrane distributed via Nobel Biocare). Research-stage products include Novomaix (dermal regeneration), Neuromaix (nerve regeneration conduits), and E.CH.O (bone-cartilage scaffold). All products are developed and produced in Germany using proprietary collagen processing and open-porous scaffold technologies.
Differentiator
Problem solved
Functional benefit
Brands
- Remaix: Bioresorbable collagen barrier membrane for guided bone regeneration (GBR) and guided tissue regeneration (GTR) in dental applications.
- Neuromaix
- Novomaix
- E.CH.O
- creos xenoprotect
- ACI-Maix
- Cartimaix
Products and services
- Remaix Bioresorbable dental barrier membrane for guided bone regeneration (GBR) and guided tissue regeneration (GTR), composed of highly purified porcine collagen and elastin fibers. Provides reliable barrier function while supporting natural tissue regeneration.
- Neuromaix Nerve regeneration collagen conduits with internal longitudinal microchannels for directional nerve fiber regeneration in reconstructive surgery for peripheral nerve defects.
- Novomaix Dermal regeneration matrix intended to stimulate regeneration of dermal tissue as a basis for attachment of autologous split-skin mesh grafts or cultured keratinocyte sheets for treatment of full-thickness skin defects after burns or plastic reconstructive surgery.
- E.CH.O (Endochondral Cartilage Ossification) Mechano-hybrid scaffold for endochondral ossification of large bone and bone-cartilage defects.
- ACI-Maix Collagen membrane used in the manufacture of MACI (autologous cultured chondrocyte implant) for treatment of symptomatic full-thickness cartilage defects of the knee.
- Cartimaix Bioresorbable collagen membrane for coverage of joint cartilage defects following bone marrow-stimulating procedures, used for traumatic and degenerative lesions on surfaces of large joints.
- creos xenoprotect Dental collagen barrier membrane for tissue regeneration procedures, distributed by Nobel Biocare. Features high tensile strength, excellent handling, and long stability against degradation without chemical crosslinking.
- Contract Manufacturing Services Contract manufacturing services for pharmaceutical companies and medical device manufacturers, producing collagen-containing products to specification under GMP standards.
- Pharmaceutical Excipients Development and supply of pharmaceutical excipients based on collagen for applications in medicine and biotechnology.
Quantifiable outcome
- Slower biodegradation rate compared to other non-crosslinked collagen membranes in comparative studies
- +2 more outcomes
Companies that use Matricel
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
Matricel technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Matricel partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core, major and minor.
- Nobel BiocarecoreGlobal distribution partnership for dental collagen barrier membranes under the creos xenoprotect brand. Distribution covers Europe, US (FDA 2013), Canada (2015), and Mexico/Central America (2015 COFEPRIS approval).
- Vericel CorporationcoreLong-term supply agreement for ACI-Maix collagen membrane used in MACI (Matrix-Induced Autologous Chondrocyte Implantation) for treating symptomatic full-thickness cartilage defects of the knee. Matricel previously supplied membranes when MACI was marketed by Genzyme outside the US.
- 2med GmbHmajorDistribution cooperation for Cartimaix bioresorbable collagen membrane for orthopedic cartilage regeneration. 2med distributes in Germany and Austria, combining Cartimaix with their NanoFx system for nanofrakturierung procedures.
- Genzyme Corporation (Sanofi)majorClose cooperation in the field of articular cartilage regeneration. Genzyme previously marketed MACI using Matricel's ACI-Maix collagen membrane outside the US.
- curasan AGmajorJoint development of new collagen-ceramic foam products for clinical use in bone regeneration. Development of composite sponge products combining ceramic bone substitutes with collagen.
- EuroSkinGraft ConsortiummajorEU 7th Framework Programme project coordinated by PD Dr. Ernst Reichmann, University of Zurich. Multicenter clinical studies comparing innovative treatment concepts for full thickness dermal wounds in Switzerland, Netherlands, and Germany.
- Clinic for Plastic and Reconstructive Surgery, RWTH AachenmajorClose cooperation on nerve regeneration project (Neuromaix) developing collagen nerve guidance conduits with internal guidance structures for reconstructing peripheral nerve defects.
- Burns Research Institute, Beverwijk, NLmajorClinical research cooperation with Prof. Middelkoop on Novomaix dermal regeneration matrix for burn wound treatment.
- Pauwelsklinik AachenminorClinical research partner for nerve regeneration and other tissue engineering projects.
- Nederlandse Brandwonden Stichting (Dutch Burns Foundation)minorFunding and research support for preclinical studies on Novomaix dermal regeneration matrix.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
Matricel competitors and assessment
Company assessmentBroad incumbents
- Smith+Nephew: Global medical device leader with wound management (including collagen-based wound dressings) and orthopedics franchises — a comparable large incumbent across multiple of Matricel's served indications.
- Coloplast: Danish wound and skin care company with collagen-containing wound care products (e.g., Biatain, Purilon) competing in the same hospital/burn wound center channel where Matricel sells Novomaix directly.
- Stryker: Global orthopedic medical device giant with an extensive orthobiologics portfolio (bone graft substitutes, cartilage repair, sports medicine) — directly comparable on the orthopedic side of Matricel's business including Cartimaix and ACI-Maix.
- Integra LifeSciences: Multi-billion-dollar US medical device company with broad regenerative medicine portfolios including Integra Dermal Regeneration Template and NeuraGen nerve conduits — directly comparable to Matricel's Novomaix (dermal) and Neuromaix (nerve) programs.
- MiMedx: US publicly-traded regenerative medicine company focused on wound care and surgical recovery with placental/amniotic and other biologic skin substitutes — direct overlap with Matricel's burn/skin regeneration positioning.
- Organogenesis: Public regenerative medicine company with Apligraf and Dermagraft skin substitute products in wound care/burn indications, directly comparable to Matricel's Novomaix dermal regeneration matrix on therapeutic indication.
Direct peers
- Vericel Corporation: US cell-therapy company marketing MACI (autologous chondrocyte implantation) which uses Matricel's ACI-Maix collagen membrane — both a key customer and adjacent competitor in cartilage regeneration.
- botiss biomaterials: Germany-based dental regeneration specialist offering collagen membranes (e.g., collacone, Jason membrane) directly competing with Matricel's Remaix and creos xenoprotect in the same European dental customer base.
- Axogen: US nerve repair specialist selling Avance nerve allograft and related products for peripheral nerve reconstruction — a direct competitor to Matricel's Neuromaix collagen nerve guidance conduit program.
- Geistlich Biomaterials: Swiss-headquartered leader in dental bone and tissue regeneration, including the widely used Bio-Gide collagen membrane — Matricel's most direct functional competitor in guided bone/tissue regeneration (GBR/GTR) membranes.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Matricel social profiles
Digital presenceMatricel financial estimates
Financial estimateRevenue estimate
Valuation estimate
Matricel leadership team
Management profileNumber of profiles
Profiles4 records
Matricel funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Matricel M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Matricel
What does Matricel do?
Matricel develops, manufactures, and markets bioresorbable Class III collagen implants for regenerative medicine applications, including dental barrier membranes (Remaix, creos xenoprotect), cartilage regeneration membranes (ACI-Maix, Cartimaix), dermal regeneration matrices (Novomaix), nerve guidance conduits (Neuromaix), and bone-cartilage scaffolds (E.CH.O). The company also provides contract manufacturing services for collagen-containing products to pharmaceutical and medical device firms.
Is Matricel a public or private company?
Matricel is a private company. It is classified as corporate owned and is currently operating.
When was Matricel founded?
Matricel was founded in 2001. It employs 11 to 50 people.
Where is Matricel based?
Matricel is headquartered in Herzogenrath, Germany, in the Europe region.
How does Matricel make money?
Three revenue lines are on record. Medical Device Sales are the primary driver. The others are contract Manufacturing and pharmaceutical Excipients.
Who are Matricel's main competitors?
Broad incumbents on record are Smith+Nephew, Coloplast, Stryker, Integra LifeSciences, MiMedx and Organogenesis. Direct peers are Vericel Corporation, botiss biomaterials, Axogen and Geistlich Biomaterials.
Does Matricel have an API?
No public API is recorded for Matricel.
What industry is Matricel in?
Matricel's product category is Regenerative Medicine Medical Devices. Its primary akta.pro industry code is HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials), with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its SIC code is 3842.